Thursday, November 12, 2026

Goldman Sachs exits retail banking with $3B+ asset sales, refocuses on institutional wealth after $3.8B consumer losses

Goldman Sachs has completed its exit from consumer banking, selling Marcus loans, GreenSky, and its wealth management unit for over $3 billion after losing $3.8 billion in retail operations between 2020-2022. The retreat mirrors moves by European universal banks including Deutsche Bank and Barclays, which scaled back retail operations in recent years to focus on institutional clients. JPMorgan takes over Goldman's Apple Card program in 2026.

ViaNews Editorial Team

February 21, 2026

Goldman Sachs exits retail banking with $3B+ asset sales, refocuses on institutional wealth after $3.8B consumer losses
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Goldman Sachs has sold its Marcus loan portfolio, GreenSky consumer lending platform, and Personal Financial Management unit for over $3 billion combined, completing a strategic retreat from retail banking that parallels similar exits by Deutsche Bank and Barclays in recent years. The sales reverse Goldman's 2016 retail expansion, which lost $3.8 billion between 2020 and 2022.

JPMorgan will assume the Apple Card credit card program in 2026, ending Goldman's partnership that began in 2019. Customer acquisition costs at Goldman exceeded industry benchmarks, while consumer loan servicing averaged $13,000 per origination at U.S. government-backed lenders Fannie Mae and Freddie Mac—costs that specialized fintech firms have reduced through automation.

The bank formed Capital Solutions Group in 2025 to consolidate institutional wealth operations, acquiring Industry Ventures and Innovator Capital Management the same year. Goldman redirected capital from consumer products into alternative investments and fund management, where institutional business generated 15%+ return on equity in 2024 versus mid-single-digit returns in retail banking.

Creative Planning, which bought Goldman's wealth unit in 2023, manages $300 billion in client assets with cost-to-income ratios 15-20 percentage points below traditional private banks through automated portfolio rebalancing and tax-loss harvesting. The efficiency gap reflects broader industry trends: specialized financial providers are projected to capture 60% of new retail customers by 2028, up from 35% in 2023.

Goldman's investment banking division advised on $1.2 trillion in M&A transactions in 2024, maintaining top-three global rankings. The consumer exit affects approximately 3,000 employees across lending, deposits, and wealth management, with 40% reassigned to institutional divisions and remaining staff absorbed by acquiring firms.

Universal banks globally face pressure to match automation efficiencies of specialized competitors or exit retail segments. HSBC and Standard Chartered have similarly refocused on Asia-Pacific wealth management and corporate banking, withdrawing from mass-market retail in multiple markets since 2020.


Sources:
1 News Report, "Market risk a la 2022" (March 20, 2026)
2 Nasdaq, "U.S. stocks' decline persists despite efforts to minimize concerns about the Iran war, oil prices su" (March 20, 2026)
3 Yahoo Finance, "Indian rupee, bonds set to extend rough patch as Mideast war enters fourth week" (March 23, 2026)
4 Yahoo Finance, "Stock market today: Dow, S&P 500, Nasdaq futures fall as 4-week down spiral continues, Trump thr" (March 22, 2026)
5 Yahoo Finance, "Is JPMorgan Chase & Co. (JPM) A Good Stock To Buy Now?" (March 16, 2026)

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com